These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 9184396)

  • 1. Fibrinogen heterogeneity in homozygous plasminogen deficiency type I: further evidence that plasmin is not involved in formation of LMW- and LMW'-fibrinogen.
    Dempfle CE; Pfitzner SA; Schott D; Niessen KH; Heene DL
    Thromb Haemost; 1997 May; 77(5):879-83. PubMed ID: 9184396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Demonstration of heterodimeric fibrinogen molecules partially conjugated with albumin in a novel dysfibrinogen: fibrinogen Mannheim V.
    Dempfle CE; George PM; Borggrefe M; Neumaier M; Brennan SO
    Thromb Haemost; 2009 Jul; 102(1):29-34. PubMed ID: 19572064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Purification and characterization of 3 fibrinogens with different molecular weights obtained from normal human plasma.
    Holm B; Nilsen DW; Kierulf P; Godal HC
    Thromb Res; 1985 Jan; 37(1):165-76. PubMed ID: 3983897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The viscosity of fibrinogen subfractions and of EDTA denatured fibrinogen do not differ from that of native fibrinogen.
    Jensen T; Halvorsen S; Godal HC; Sandset PM; Skjønsberg OH
    Thromb Res; 2004; 113(1):51-6. PubMed ID: 15081565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abnormal fibrinogen heterogeneity and fibrinolytic activity in advanced liver disease.
    Lipinski B; Lipinska I; Nowak A; Gurewich V
    J Lab Clin Med; 1977 Jul; 90(1):187-94. PubMed ID: 406338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrinogen heterogeneity in cancer, in occlusive vascular disease, and after surgical procedures.
    Lipinska I; Lipinski B; Gurewich V; Hoffmann KD
    Am J Clin Pathol; 1976 Dec; 66(6):958-66. PubMed ID: 998569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the in vitro fibrinolytic activities of low and high molecular weight single-chain urokinase-type plasminogen activator.
    de Munk GA; Groeneveld E; Rijken DC
    Thromb Haemost; 1993 Sep; 70(3):481-5. PubMed ID: 8259553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interactions of human blood platelets with three circulating plasma fibrinogens of different molecular weights.
    Thorsen LI; Holm B; Brosstad F; Solum NO
    Thromb Res; 1987 Sep; 47(6):683-92. PubMed ID: 3686483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitation of the three normally-occurring plasma fibrinogens in health and during so-called "acute phase" by SDS electrophoresis of fibrin obtained from EDTA-plasma.
    Holm B; Godal HC
    Thromb Res; 1984 Aug; 35(3):279-90. PubMed ID: 6431629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Studies on fibrinogen heterogeneity in disseminated intravascular coagulation].
    Yamauchi M
    Hokkaido Igaku Zasshi; 1982 Jul; 57(4):425-36. PubMed ID: 7173813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of alphaA-crystallin from high molecular weight aggregates in the normal human lens.
    Fujii N; Awakura M; Takemoto L; Inomata M; Takata T; Fujii N; Saito T
    Mol Vis; 2003 Jul; 9():315-22. PubMed ID: 12847419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence of intramolecular cross-linked A alpha.gamma chain heterodimers in plasma fibrinogen.
    Siebenlist KR; Mosesson MW
    Biochemistry; 1996 May; 35(18):5817-21. PubMed ID: 8639542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular conversions of recombinant staphylokinase during plasminogen activation in purified systems and in human plasma.
    Ueshima S; Silence K; Collen D; Lijnen HR
    Thromb Haemost; 1993 Sep; 70(3):495-9. PubMed ID: 8259556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific plasminogen activator inhibitor of placental type PAI 2 occurring in amniotic fluid and cord blood.
    Lecander I; Astedt B
    J Lab Clin Med; 1987 Nov; 110(5):602-5. PubMed ID: 3499478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence that changes in fibrinogen quality during acute phase reactions are of major importance for the amount of heparin precipitable fraction (HPF).
    Holm B; Godal HC
    Thromb Res; 1985 Aug; 39(4):449-58. PubMed ID: 4049325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphonuclear elastase in patients with homozygous type I plasminogen deficiency and ligneous conjunctivitis.
    Mingers AM; Philapitsch A; Schwarz HP; Zeitler P; Kreth HW
    Semin Thromb Hemost; 1998; 24(6):605-12. PubMed ID: 10066157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The stimulatory capacity of soluble fibrin prepared from high and low molecular weight fibrinogen on plasminogen activation.
    Halvorsen S; Skjønsberg OH; Godal HC
    Blood Coagul Fibrinolysis; 1993 Feb; 4(1):133-7. PubMed ID: 8457641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunovisualization of fibrinogen A alpha-chain heterogeneity in normal plasma and plasma from patients with DIC or on streptokinase therapy.
    Grøn B; Bennick A; Nieuwenhuizen W; Bjørnsen S; Brosstad F
    Thromb Res; 1988 Dec; 52(5):413-24. PubMed ID: 3222783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of magnesium on fibrin formation from lower molecular weight (LMW) fibrinogen.
    Lipinski B; Lipinska I
    Magnes Res; 2000 Dec; 13(4):233-7. PubMed ID: 11153893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies on the functionality of newly synthesized fibrinogen after treatment of acute myocardial infarction with streptokinase, increase in the rate of fibrinopeptide release.
    Reganon E; Vila V; Aznar J; Lacueva V; Martinez V; Ruano M
    Thromb Haemost; 1993 Dec; 70(6):978-83. PubMed ID: 8165621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.